2000. MALALTIES MENTALS. PROJECTES FINANÇATS

Dr  Enric Álvarez Martínez

F. Cuevillas, M. Barbanoj, R. Antonijoan, E. del Rio, M. Gómez-Pardo, M. Baiget. Análisis del genotipo del enzima NAT2. Resultados en la población española. Quimica Clinica 2002; 21: 371

F. Cuevillas, M. Barbanoj, R. Antonijoan, E. del Rio, M. Gómez-Pardo, M. Baiget. Aplicaciones de la PCR a tiempo real, sistema Taqman, al estudio genotípico del complejo citocromo P450. Quimica Clinica 2002; 21: 371

M. Baiget, J. Perez de los Cobos, E. del Rio, V. Volpini, M. Gómez-Pardo, E. Alvarez. DRD2 allele frequencies and linkage desequilibria in Spanish subjects. Am J of Medical Genetics 2002; 114: 788.

J. Pérez de los Cobos, M. Baiget, J. Trujols, L. Gil, E. del Rio, V. Volpini, B. Gonzalvo, E. Alvarez. DRD2 TaqI genotype frequencies in heroin-dependent methadone-maintained patients from Spain. Am J of Medical Genetics 2002; 114: 782.

J. Pérez de los Cobos, J. Trujols, L. Gil, E. Del Rio, M. Cardús, F. Batlle, E. Alvarez, M. Baiget. Opiates in hair during methadone treatment of heroin-dependent patients with the DRD2 A1 allele. Am J of Medical Genetics 2002; 114: 782.

P. Vinuesa, E. Grasa, V. Perez, I. Corripio, M. Baiget, E. Alvarez. Polymorphisms of dopamine D2 and D4 receptor genes as predictors of therapeutic response to haloperidol and clozapine.  European Neuropsychopharmacology 13, supp 4, S294, 2003

E. Masoliver, A. Menoyo, V. Perez, E. Grasa, M. Baiget, D. Puigdemont, E. Alvarez. The 5-HTTLPR polymorphism in the SCL6A4 gene is associated with antidepressant induced mania in bipolar disorders. European Neuropsychopharmacology 13, supp 4, S195, 2003

P. Vinuesa, S. Oller, J. Perez, I. Corripio, V. Perez, E. Alvarez. Outcome of bipolar disorders. A naturalistic study.  European Neuropsychopharmacology 13, supp 4, S221, 2003

A. Menoyo, E. Del Rio, M. Baiget. Characterisation of variant alleles of cytochrome CYP2D6 in a Spanish population.  Cell Biochemistry and Function. 2005; 23:1-5

I.Corripio, A. Catafau, V. Perez, D. Puigdemont, E. Mena, Y. Aguilar, I. Carrió, E. Alvarez. Striatal dopaminergic D2 receptor occupacy and clinical efficacy in psychosis exacerbation: a 1231-IBZM study with ziprasidone and haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005; 29: 91-96.

I.Corripio, V. Perez, A. Catafau, E. Mena, I. Carrió, E. Alvarez. Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis.  Neuroimage 2005; (available on line www.elsevier.com/locate/ynimg).

E. Masoliver, A. Menoyo, V. Perez, E. Del Rio, J. Perez, E. Alvarez, M. Baiget. The 5-HTTLPR polymorphism in the serotonin transporter gene is associated with antidepressant induced mania in bipolar disorders. Psychiatric Genetics 2006; 16:25-29.

J. Pérez de los Cobos, Ll. Trujols, E. Del Rio, V. Volpini, M. Baiget, E. Alvarez. Male limited allelic, genotypic and haplotypic associations of DRD2 TaqI A and DRD4 exon III VNTR polymorphisms with heroin dependence in Spanish subjects. (submitted)

Dr  Santiago Ambrosio Viale

C.Gómez-Santos, I.Ferrer, A.F.Santidrián, M.Barrachina, J.Gil, S.Ambrosio. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res. 73: 341-350 (2003).

C Gómez-Santos, M Barrachina, P Giménez-Xavier, E Dalfó, I Ferrer, S Ambrosio. Induction of C/EBPB and GADD153 transcription factor expression by dopamine int4 human neuroblastoma cells. Relationship with fue increase in alfa-synuclein and cell damage. Brain Res Bull. 2005 Feb 15;65(1):87-95

C Gómez-Santos,I Ferrer,A F. Santidrián,M Barrachina,J Gil,S Ambrosio. Dopamine Induces Autophagic Cell Death and a-Synuclein Increase in Human N euro bIas toma SH-SY5Y Cells. Journal of Neoroscience Research 73:341-350 (2003)

Giménez-Xavier P., Gómez-Santos C., Castaño E., Boada J., Unzeta M., Sanz E., Ambrosio S. The decrease of reductive cell power has a prominent role in dopamine toxicity. Biochim. Biophys. Acta (2006), (in press).

Dr  Lourdes Arbonés de Rafael

Dr  Javier Felipe Oroquieta

Fotaki V., Martinez de Lagran M., Estivill X., Arbones ML., Dierssen M. Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity. Behav. Neurosci. 118:815-821, 2004.

Benavides-Piccione R., Dierssen M., Ballesteros-Yánez TI., Martínez de Lagrán M., Arbonés ML., Fotaki V.,  De Felipe J., Elston GN. Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiol. Dis. 20:115-122, 2005.

Martínez de Lagrán M., Bortolozzi A., Millán O., Gispert JD., González JR., Arbonés ML., Artigas F., Dierssen M. Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, Dyrk1A+/-. (in revision)

Dr  Joaquín V. Arribas López

Martínez-Arca S., Hurtando-Küttner M., Borroto A., and Arribas J. Recycling of cell surface proTGF-alpha regulates EGFR activation. J Biol Chem 280, 36970-3697 (2005)

Villanueva de la Torre T., Bech-Serra J. J., Ruiz-Paz S., Baselga J., Arribas J. Inactivating mutations block the Tumor Necrosis Factor-Alpha Converting Enzyme in the early secretory pathway. Biochem Biophys Res Commun 314, 1028-1035 (2004)

Borroto A., Ruíz-Paz S., Borrell-Pagès M., Villanueva de la Torre T., Merlos-Suárez A., Blobel C. P., Baselga J., and Arribas J. A specific mechanism mediates the intracellular trafficking and activation of TACE. J Biol Chem 278, 25933-25939 (2003)

Dr  Francesc Artigas Pérez

Dr  Víctor Pérez Sola

Dr  Montserrat Estorch Cabrera

Adell A, Celada P, Abellán MT, Artigas F. (2002) Origin and functional role of the extracellular 5-HT in the midbrain raphe nuclei. Brain Res Rev 39:154-180

Romero L., Celada P., Martín-Ruiz R., Díaz-Matix L., Mourelle M., Delgadillo J., Hervás I., Artigas F. Modulation of the serotonergic function in rat brain by VN2222, a 5-HT reuptake inhibitor with 5-HT 1A receptor agonist. Neuropsychopharmacology 28: 445-456 (2003)

Puig MV., Celada P., Díaz-Mataix L., Artigas F. In vivo modulation of the activity of pyramidal neurons in the rat media' prefrontal cortex by 5-HT 2A receptors. Relationship to thalamocortical afferents Cereb Cortex 13: 870-882 (2003) 

Bortolozzi A., Amargós M., Adell A., Díaz-Mataix L., Serrats J., Pons S., Artigas F. In vivo modulation of 5-HT release in mouse prefrontal cortex by local 5-HT 2A receptors. Effect of antipsychotic drugs. Eur J Neurosci 18: 1235-1246 (2003)

Amargós-Bosch M., Bortolozzi A., Puig MV., Serrats J., Adell A., Celada P., Toth M., Mengod G., Artigas F. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in prefrontal cortex. Cereb Cortex 14: 281-299. (2004)

Bortolozzi A., Amargós-Bosch M., Toth M., Artigas F., Adell A. In vivo release of serotonin in the dorsal raphe nucleus of 5-HT 1Aeceptor knockout mice. J Neurochem (in press) (2004)

Celada P., Puig MV., Amargós-Bosch M., Adell A., Artigas F. Therapeutic role of 5-.HT 1A and 5-HT 2A receptors in depression. J Psychiatry Neurocsi 29:252-265

Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100-1109.

Puig MV., Santana N., Celada P., Mengod G., Artigas F. (2004) In vivo excitation of GABA interneruons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex 14: 1365-1375

Puig MV., Artigas F., Celada P. (2005) Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: Involvement of serotonin and GABA. Cereb Cortex 15:1-14.

Adell A., Celada P., Abellán MT., Artigas F. (2002) Origin and functional role of the extracellular 5-HT in the midbrain raphe nuclei. Brain Res Rev 39:154-180

Adell A., Artigas F. (2004) The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev 28:415-431

Adell A., Castro E., Celada P., Bortolozzi A., Pazos A., Artigas F. (2005) Strategies for producing faster acting antidepressants. Drug Discovery Today 10:578-585

Dr  Manuel-José Barbanoj Rodríguez

Barbanoj MJ., Valle M., Kulisevsky J., Pérez V., Gambús P. Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario. Methods and Findings in Éxperimental and Clinical Pharmacology, 24 (suppl: D) 139-144 (2002)

Grasa E., Gich I., Pérez V., Torrubia R., Barbanoj MJ. Development of the Spanish version of the schizotypal personality questionnaire (SPQ).Schizophrenia Research (sent)

Giménez S., Clos S., Romero S., Grasa E., Morte A., Barbanoj MJ. Effects of olanzapine, risperidona and haloperidol on sleep after a single oral morning dose in healthy volunteers  Psychopharmacology (sent)

Valle M., Grasa E., Yritia M., Romero S., Barbanoj MJ. Olanzapine plasma cocentrations and EEG effects relationship in healthy volunteers: a population pharmacokinetic-pharmacodynamic modelling approach. International Journal of Neuropyschopharmacology. (sent)

Giménez S., Clos S., Morte A., Romero S., Grasa E., Barbanoj MJ. Changes on sleep architecture after antipsychotic morning single oral doses in healthy subjects. 17th Congress of the European Sleep Research Society. October 5-9, 2004. Prague, República Checa.  Journal of Sleep Research 13(suppl 1), 2004: Abstract 267

Dr  Miquel Bernardo Arroyo

Bernardo M., Baeza I., Deulofeu R., Goti J., Plana MT.. Plasma Homovanillic Acid Differences between predominants possitive and Negative First-episode Schizophrenia patients. International Congress on Schizophrenia Research. Colorado, 2003. Schizophrenia Research 2003; p. 98.

Baeza I.; Bernardo M.; Pérez-Gómez. M.; Junqué C., Deulofeu D. Psychopathology, Attentional Functioning and Plasma Homovanillic Acid Levels in Early Onset and Later Onset Schizophrenia. International Congress on Schizophrenia Research. Colorado, 2003. Schizophrenia Research 2003; p. 3.

Parramón G.; Baeza I.; Deulofeu R.; Torra M.; Parellada E; Bernardo M. El ácido homovanílico como marcador evolutivo en pacientes esquizofrénicos en tratamiento antipsicótico. VIII Congreso Nacional de Psiquiatría. Bilbao, 2004. Psiquiatría Biológica 2004; 11 (Extraordin 1):96

Baeza I.; Romero A.; Mané A.; Deulofeu R.; Castro J.; Bernardo M. Plasma homovanillic acid response to risperidone in adolescent first episode psychosis: preliminary results. Schizophrenia Research Congress, USA, 2004. Schizophrenia Research 2004; 70(1)(suppl) p.113

Bernardo M., Baeza I., Deulofeu R., Mateos JJ. Evidencias de anomalías dopaminérgicas en esquizofrenia, Dopamina y Esquizofrenia 2004 Ed. Mayo; 11: 141-147. (ISBN 84-96122-12-3)  Dep legal: B-41.325-03.

Dr  Teresa Boget Llucià

R Penadés, T Boget, R Catalán, C Gastó, M Salamero. La rehabilitación cognitiva en la esquizofrenia: estado actual de la cuestión. Revista Psiquiatría Facultad Medicina de Barcelona. 29 (6): 380-384. 2002.

Penadés R., Catalán R., Salamero M., Boget T., Puig O., Guarch J., Gastó C. Cognitive Remediation Therapy for outpatients with chronic schizophrenia: a controlled and randomized trial. Schizophrenia Research (in revision)

Dr  Jordi Camarasa Garcia

D. Pubill, E. Verdaguer, F.X. Sureda, A. Camins, M. Palias, J. Camarasa, E. Escubedo. Carnosine prevents methamphetamine-induced gliosis but not dopamine-terminal loss in rats. Eur. J. Pharmacol. (2002) 448:165-168.

D. Pubill, A.M. Can ud as, M. Palias, A. Camins, J. Camarasa, E. Escubedo. Different glial response against methamphetamine and methylenedioxymetham phetam i ne-i nd uced neu rotoxicity Naunyn Schmiedeberg's Arch. Pharmacol. (2003) 367:490-499.

A. Jiménez, E. García, E. Verdaguer, D. Pubill, FX. Sureda, A. Canudas, E. Escubedo, J. Camarasa, A. Camins, M. Palias, Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicol. Appl. Pharmacol. (2004) 196:223-234.

D. Pubill, C. Galiana, A. Camins, M. Palias, J. Camarasa, E. Escubedo. Free radical production induced by methamphetamine in rat striatal synaptosomes. British Joumal of Pharmacology (2004) (sent)

E. Escubedo, C. Chipana, M. Pérez-Sánchez, J. Camarasa, D. Pubill, Methyllycaconitine Prevents Methamphetamine-Induced Effects in Mouse Striatum: Involvement of α7 Nicotinic Receptors. The Journal of Pharmacology and Experimental Therapeutics (2005) Vol.315, N.2, 658-667

E. Verdaguer, D. Pubill, V. Rimbau, A. Jiménez, E. Escubedo, J. Camarasa, M. Pallas, A. Camins. Evaluation of neuronal cell death by Laser Scanning Cytometry. Brain Res. Protocols (2002) 9:41-48.

E. Verdaguer, E. García-Jordà, A.M. Canudas, E. Domínguez, A. Jiménez, D. Pubill, E. Escubedo, J. Camarsa, M. Pallàs, A. Camins. Kainic acid-induced apoptosis in cerebellar granule neurons: an attempt at cell cycle re-entry. Neuroreport (2002) 13:413-416.

D. Pubill, C. Galiana, A. Camins, M. Pallàs, J. Camarasa, E. Escubedo. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharmacol (2005) 204:57-68

Dr  Xavier Carné Cladellas

Lafuente A., Bernardo M.,  Mas S.,  Crescenti A.,  Aparici M.,  Deulofeu R.,  Mane A.,  Catalan R.,  Carne X. Polymorphism of Dopamine D2 receptor (TaqIA, TaqIB, and -141C Ins/Del) and dopamine degradation enzyme (COMT) genes and extrapyramidal symptoms in patients with schizophrenia. (publication pending)

Lafuente A., Bernardo M., Mas S., Crescenti A., Aparici M., Deulofeu R., Mane A., Catalan R., Carne X. -141 C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. (publication pending)

Lafuente A., Bernardo M., Mas S., Crescenti A., Aparici M., Gasso P., Catalan R., MAteos J.J., Lomeña F., Perellada E.The VNTR polymorphism of the dopamine transporter (DAT) gene and striatal DAT binding and extrapyramidal symptoms induced by antipsychotic treatment in schizophrenia. (publication pending)

 

Dr  Jordi Casademont Pou

 

Casademont J., Perea M., Lopez S., Beato A., Miro O., Cardellach F. Enzymatic diagnosis of oxidative phosphorylation defects on muscle biopsy: Better on tissue homogenate or on a mitochondria-enriched suspension? Med Sci Monit. 2004 Sep;10 (9):49-53.

Casademont J., Rodriguez-Santiago B.,  Miró O., Beato A., López S., Nunes V., Cardellach F. Mitochondrial respiratory chain in brain homogenates: Activities in different brain areas in patients with Alzheimer's disease. Aging Clinical and Experimental Research 2005; 17:1-7

Casademont J., Sanjurjo E., Garrabou G., Miró O. Diagnosis of mitochondrial dysfunction in HIV-infected patients under highly active antiretroviral therapy: possibilities beyond the standard procedures. Antivir Therapy 2005; 10 (suppl 2):M65-71

Miró O., López S., Fernández-Solà J., Garrabou G., Pedrol E., Badia E., Martínez E., Cardellach F., Gatell JM., Casademont J. HIV infection, antiretrovirals and apoptosis: studies on skeletal muscle. AIDS REs Hum Retrovir 2005; 21:702-705

Garrabou G., Sanjurjo E., Miró O., Martínez E., Infante AB., López S., Cardellach F., Gatell JM., Casademont J. Non-invasive diagnosis of mitochondrial dysfunction in HAART-related hyperlactatemia. J Infect Dis 2006; 42:584-585

Casademont J., Miró O., Cardellach F. Secondary defects of the mitochondrial respiratory chain: The examples of neuroleptic use, CO toxicity and HIV treatment. En Villarroya F (ed.) New frontiers in mitochondrial biogenesis and disease. Research Singpost. Keral, India 2005, pp 1-29

Casademont J., López S., Beato A., Miró O., Cardellach F. The importance of simultaneous study of muscle homogenate and mitochondrial enrichec suspensions in the diagnosis of mitochondrial respiratory chain disorders. Xth International Congress on neuromuscular Diseases. Vancouver, July 2002. J Neuromusc Dis 2002 ; 199(S) : 69

Picón M., Casademont J., Beato A., Miró O., Pons A., Bernardo M., Cardellach F. Funcionalismo de la cadena respiratoria mitocondrial en linfocitos de pacientes en tratamiento con neurolépticos atípicos. LV Reunión Anual de la Sociedad Española de Neurología. Barcelona, Noviembre 2003. Neurología 2003; 18:210

Casademont J., López S., Picón M., Garrabou G., Infante A., Miró O., Cardellach F. The effect of 'atypical' antipsychotics on the OXPHOS system in peripheral blood mononuclear cells. Euromit 6. Nijmegen, July 1-4 2004. BBA (Bioenergetics) 2004: 1657: 50-1

Dr  Bernardo Castellano López

Dr  José Borrell Andres

Ribó D., Romero E., Acarin L., González B., Borrell J., Castellano B. Astroglial and microglial cells in the prenatal immune challenge model. VI European Meeting on GLial Cell Function inHealth and Disease. Berlin (Alemania) Setiembre 2003. Glia (2003) suppl.2: 65 (P208)

Ribó D., Romero E., Acarin L., González B., Borrell J., Castellano B. Células de microglia y astroglia en el modelo de choque endotóxico prenatal. X Congreso de la Sociedad Española de Neurociencias, Lleida, Setiembre 2003 Revista de Neurologia 37 (12): 1121 (P17), (2003)

Romero E., Ali C. Molina-Holgado E., Castellanos B., Guaza and J Borrell C. Neurobehavioral and Immunological Consequences of Prenatal Immune Activation in Rats. Influence of Antipsychotics  Mol. Psychiatry(sent)

Dr  Ana M. Catafau Alcántara

 

Catafau AM., Perez V., Penengo M., Bullich S.,Danus M., Puigdemont D., Pascual JC., Corripio I., Llop J., Perich J., Alvarez E. SPECT of Serotonin Transporter using 123I-ADAM optimal imaging time after bolus injection and long term test-retest in healthy volunteers JNucl Med 05;46:1301-1304.

 

Dr  Jorge A. Cervilla Ballesteros

Villalta-Gil V., Vilaplana M., Ochoa S., Dolz M., Usall J., Haro JM., Almenara J., González JL., Lagares C.  and the NEDES Group . Four symptom dimensions in schizophrenia outpatients. Comprehensive Psychiatry, (in press)

Villalta V., Vilaplana M., Ochoa S., Dolz M., Haro JM., Cervilla J. La Función Cognitiva Frontal se Asocia Inversamente a la Dimensión Negativa de la Esquizofrenia. Actas Esp Psiquiatr 2003; 31 núm. extraordinari 1: 22

Dr  Mara Dierssen Sotos

 

Dierssen M., Fotaki V., Martínez de Lagrán M., Gratacòs M., Fillat C., Estivill X Neurobehavioral development of two mouse lines commonly used in transgenic studies. Pharmacol Biochem Behav 73: 19-25, 2002

Baamonde C., Lumbreras MA., MartInez-Cue C., Vallina IF., Florez J., Dierssen M. Postnatal handling induces long-term modifications in central beta-noradrenergic signalling in rats. Stress 5: 137-47, 2002

Gallego X., Armengol Ll., Estivill X., Dierssen M. Transgenic mice over-expressing alpha3nAChR, alpha5nAChR and beta4nAChR receptors present mild anxiety-like behavior and panic reaction in mouse, (in preparation).

Amador A., Gallego, X., Sabriá J., Dierssen M. Transgenic mice over-expressing alpha3nAChR, alpha5nAChR and beta4nAChR receptors present increased tendency to alcohol self-administration, (in preparation).

Dr  Xavier Estivill Pallejà

Dr  Rocío Martín-Santos Laffon

Pujana MA, Nadal M, Guitart M, Armengol L, Gratacos M, Estivill X. Human chromosome 15q11-q14 regions of rearrangements contain clusters of LCR15 duplicons. Eur J Hum Genet 2002,10:26-35

Armengol L, Gratacos M, Pujana MA, Ribases M, Martin-Santos R, Estivill X. 5' UTR-region SNP in the NTRK3 gene is associated with panic disorder. Mol Psychiatry 2002, 7:928-930

Domschke K, Kuhlenbaumer G, Schirmacher A, Lorenzi C, Armengol L, DiBella D, Gratacos M, Garritsen HS, Nothen MM, Franke P, Sand P, Fritze J, Perez G, Maier W, Sibrowski W, Estivill X, Bellodi L, Ringelstein EB, Arolt V, Martin-Santos R, Catalano M, Stogbauer F, Deckert J. Human nuclear transcription factor gene CREM: Genomic organization, mutation screening, and association analysis in panic disorder. Am J Med Genet 2003 15: 70-8. 12555

L Armengol, MA Pujana, J Cheun, SW Scherer, X Estivill. Enrichment of segmental duplications in regions of breaks of synteny between the human and mouse genomes suggest their involvement in evolutionary rearrangements. Human Molecular Genetics 12:2201-2208 (2003)

G Gimelli, MA Pujana, MG Patricelli, S Russo, D Giardino, L Larizza, J Cheung,; L Armengol, A Schinzel, X Estivill, O Zuffardi. Genomic inversions of human chromosome 15q11-q13 in mothers of Angelman syndrome patients with class 11 (BP2/3) deletions. Human Molecular Genetics 12:1-10 (2003). Apr 15;12 (8):849-58.

M Dierssen, M Gratacós, I Sahún,M Martín, L Armengol, Gallego, A Amador-Arjona, M Martínez de Lagrán, P Murtra, MA Pujana, I Ferrer, C Martínez-Cué, J Flórez, R Maldonado, C Fillat, Xavier Estivill. Overexpression of NTRK3 Increases Anxiety-Like Behavior and Alters Monoaminergic Circuits in Mice. Nature Neuroscience. (submitted)

M Gratacos, M Nadal, R Martín-Santos, MA Pujana, J Gago, B Peral, L Armengol, 1 Ponsa, R Miró, A Bulbena, X Estivill. A polymorphic J genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell 106: 367-379 (2001)

MA Pujana, M Nadal, M Gratacos, B peral, K Csiszar / R González- Sarmiento, L Sumoy, X Estivill. Additional complexity on human 1-chromosome 15q: identification of a set of novel duplicons (LCR15) on 15q11-q13, 15q24 and 15q26. Genome Research 11:98-111 (2001)

R. Martín-Santos, J. A. S Crippa. Trastornos de ansiedad en la asistencia primaria. En: Abordaje de los problemas de salud mental en el ámbito extrahospitalario. Col.legí de Metges de Barcelona. Barcelona, 2003; 17-31.

Dra  Lourdes Fañanás Saura

Dra  Rosa Miró Ametller

Fatjó-Vilas M.; Arias B.; Rosa A.; Miret; Domenech C.; Arrufat F.; Fañanás L. Association analysis of serotonin HTR2A and dopamine DRD2 genes and schizophrenia. American journal of Medical Genetics (Neuropsychiatric Genetics).2003. Vol. 122B (1): 143.

Fatjó-Vilas M. 2004. Estudio de los signos neurológicos menores y de las anomalías físicas menores en pacientes con trastornos del espectro esquizofreniforme y en sus familiares: análisis preliminar de su adecuación como marcadores de interés genético. Informaciones Psiquiátricas 178(4): 287-302

N. Barrantes-Vidal, M. Guitart, S. Papiol, C. Gastó, R. Penadés, S. Campanera, L. Fañanás. Heterogeneity of neurocognitive functions in schizophrenia: a comparison of carriers and non-carriers of interleukin IL1B/IL-1RN risk alleles. American journal of Medical Genetics (Neuropsychiatric Genetics) Vol. 122B (1): 171

M. Fatjó-Vilas, B. Arias, A Rosa, M. Guitart, C. Domènech, F. Arrufat, N. Barrantes-Vidal, L. Fañanás. 2004. Analysis of dopamine DRD2 gene and neurocognitive functioning in schizophrenic patients. Schizophrenia Research, 67(1)suppl.: 53-54

M. Fatjó-Vilas, S. Miret, S. Campanera, ME. Navarro, MJ. Muñoz, M. Martín, V. Tort, A. Guerra, L. Fañanás. 2004. Vulnerability markers of schizophrenia: a familial analysis of neurological soft signs and minor physical anomalies. Schizophrenia Research, 67(1) suppl.: 138. (Comunicación Pòster)

Barrantes-Vidal N., Campanera S., Muñoz MJ., Guitart M., Fatjó-Vilas M., Fañanás L. 2004. Generalised cognitive impairments in nonpsychotic relatives of schizophrenic patients. Schizophrenia Research 67(1)suppl.: 51

M. Fatjó-Vilas, A. Rosa, B. Arias, V. Peralta, MJ. Cuesta, S. Miret, ME. Navarro, M. Martín, MJ. Muñoz, L. Fañanás. 2004. A family-based association study of the BDNF and DRD3 genes in schizophrenia spectrum disorders. American journal of Medical Genetics (Neuropsychiatric Genetics) Vol. 130B (1): 139

M. Fatjó-Vilas, S. Miret, S. Campanera, ME. Navarro, M. Martín, MJ. Muñoz, A. Guerra, JM. Illa, ML. Miralles, N. Barrantes-Vidal, L. Fañanás. 2004. Neurological soft signs in schizophrenia spectrum disorders as an intermediate phenotype: a family-based study. American Journal of Medical Genetics (Neuropsychiatric Genetics) Vol. 130B (1): 140

N. Barrantes-Vidal, M. Aguilera, M. Fatjó-Vilas, MJ. Muñoz, S. Campanera, S. Miret, ME. Navarro, L. Fañanás. 2005. Neurocognitive deficits in healthy siblings of schizophrenic patients. Schizophrenia Bulletin 31(2): 349. (Comunicación Pòster)

A. Rosa, M. Gardner, MJ. Cuesta, V. Peralta, M. Fatjó-Vilas, D. Comas, L. Fañanás. 2006. Family based association study of Neuregulin 1 and schizophrenia in a Spanish simple. Schizophrenia Research, 81(suppl): 9

S. Miret, M. Fatjó-Vilas, M. Aguilera, N. Barrantes-Vidal, S. Campanera, L. Fañanás. 2006. Theory of mind and schizotypy profiles in schizophrenia-spectrum patients from a family based study: preliminary results. Schizophrenia Research, 81(suppl): 126

N. Barrantes-Vidal, M. Aguilera, M. Fatjó-Vilas, S. Campanera, MJ. Muñoz, S. Miret, A. Guerra, L. Fañanás. 2005. Neurocognitive functions in well parents of schizophrenia patients: verbal working memory deficits as a putative endophenotype of schizophrenia. Schizophrenia Research, 81(suppl): 215

M. Fatjó-Vilas, S. Miret, ME. Navarro, A. Guerra, M. Martín, ML. Miralles, JM. Illa, L. Fañanás. 2006. Neurological soft signs: is early-onset psychosis different from adult onset? Schizophrenia Research, 81(suppl): 21.

M. Fatjó-Vilas, D. Gourion, S. Campanera, C. Golberger, ME. Navarro, M. Chayet, L. Fañanás, MO. Krebs. 2006. Neurodevelopmental markers in schizophrenia: a dermatoglyphic study in patients, relatives and controls. Schizophrenia Research, 81(suppl): 216-7

M. Fatjó-Vilas, S. Miret, ME. Navarro, M. Martín, J.M. Illa, ML. Miralles, N. Barrantes-Vidal, L. Fañanás. 2006. Schizotypy profiles in parents of schizophrenia-spectrum patients and duration of untreated psychosis: preliminary results from a family based study. Schizophrenia Research, 81(suppl): 235

M. Fatjó-Vilas, S. Miret, S. Campanera, ME. Navarro, MJ. Muñoz, M. Martín, V. Tort, A. Guerra, L. Fañanás. Análisis de correlación familiar de marcadores de vulnerabilidad del neurodesarrollo en pacientes con trastornos del espectro esquizofrénico. Llibre de resums de comunicacions, pàgina 14. 1ª Reunión Nacional sobre las fases tempranas de las enfermedades mentales: las psicosis. Santander, 13-15 novembre 2003

M. Fatjó-Vilas, N. Barrantes-Vidal, S. Miret, S. Campanera, ME. Navarro, A. Guerra, V. Tort, M. Martín, MJ. Muñoz, L. Fañanás. Dimensiones esquizotípicas del SPQ-B en esquizofrenia: aproximación a la vulnerabilidad genética desde un estudio de familiares biológicos de primer grado. Llibre de resums de comunicacions, pàgina 40. 1ª Reunión Nacional sobre las fases tempranas de las enfermedades mentales: las psicosis. Santander, 13-15 novembre 2003

S. Campanera, MJ. Muñoz, S. Miret, M.E. Navarro, M. Guitart, M. Fatjó-Vilas, N. Barrantes-Vidal, L. Fañanás. Alteraciones cognitivas generalizadas en familiares sanos de pacientes esquizofrénicos. Llibre de resums de comunicacions, pàgina 11. 1ª Reunión Nacional sobre las fases tempranas de las enfermedades mentales: las psicosis. Santander, 13-15 novembre 2003. (Comunicació Oral)

N. Barrantes-Vidal, MJ. Muñoz, M. Fatjó-Vilas, M. Guitart, S Miret, ME. Navarro, L. Fañanás. A Preliminary Report on Memory Dysfunction in Healthy Siblings of Schizophrenic. Llibre de resums de comunicacions, pàgina 26. Cognition and Schizophrenia: improving real life function. Institute of Psychiatry, Londres, 16 i 17 de setembre de 2004

S. Miret, M Fatjó-Vilas, A. Rosa, V. Peralta, MJ. Cuesta, L. Fañanás. Estudio de la dimensión de manía en pacientes del espectro esquizofrénico y análisis de parámetros de neurodesarrollo alterado en un modelo etiopatogénico preliminar. Llibre de resums de comunicacions, pàgina 42 i 43. 2ª Reunión Nacional sobre las fases tempranas de las enfermedades mentales: el trastorno bipolar. Santander, 25-27 novembre 2004

Dr   Núria Ferré Suana

Sampayo M., Darbra S., Ferré N., Inhibition of NO synthesis and schyzophrenic-like symptoms. 30th Annual Meeting of the EBBS, Barcelona, 19-21 Set. 2003. Acta Neurobiologiae Experimentalis, vol 63, pp 59 Sabater M., Ferré N., Early administration of L-NAME in Wistar rats produces behavioral deficits that can be attenuated by haloperidol and clozapine. 11th Bienial European Behavioral Pharmacology Society Meeting, Barcelona, 9-12 Setembre, 2005, Pòster A-85, pp24.

Dr  Rafael Franco Fernández

Burgueño J., Enrich C., Canela E.I., Mallol J., Lluis C., Franco R. and Ciruela F. Metabotropic glutamate type 1 a receptor localizes in low density caveolin-rich plasma;" .A" membrane fractions. I J Neurochem 2003; 86: 785-791.

Burgueño J., Blake OJ., Matthew A. Benson MA., Tinsley CL., Esapa CT., Canela El., Penela P., Mallol J., Mayor F. Jr., Lluis C., Franco R.and Ciruela F. Adenosine A2A receptor interacts with the actin-binding protein a-actinin. J Biol. Chem 2003; 278: 37545-37522

Canals M., Marcellino O., Fanelli F., Ciruela F., de Benedetti P., Goldberg SRI., Fuxe K., Agnati LF., Woods AS., Ferre SI., Lluis C., Bouvier M., and Franco R. Adenosine A2A-dopamine O2 receptor-receptor heteromerization. Qualitative and Quantitative .(, assessment by Fluorescence and Bioluminescence Energy Transfer. J Biol. Chem 2003; 278: 46741-46749

Canals M., Burgueno J., Marcellino O., Cabello N., Canela El., Mallol J., Agnati L., Ferre S., Bouvier M., Fuxe K., Ciruela F., Lluis C., Franco R. Homodimerization of adenosine A2A receptors. Qualitative and Quantitative assessment by Fluorescence and Bioluminescence Energy Transfer. J Neurochemistry 2003;88 726-734

Angulo E.; Casado V.; Mallol J.; Canela EI., Viñals F.; Ferrer I.; Lluís C., Franco R. A1 Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer's Disease and Mediate both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation. Research article 

Agnati LF., Ferré S., Lluís C., Franco R., Fuxe K. Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons. Pharmacol Rev 55:509-550, 2003 

Duflot S., Riera B., Fernández-Veledo S., Casadó V., Norrnan R., Casado FJ., Lluís C., Franco R., Pastor-Anglada M. A TP-Sensitive K+ Channels Regulate the Concentrative Adenosine Transporter CNT2 following Activation by A1 Adenosine Receptors. Mollecular and Cellular Biology, Apr. 2004, p. 2710-2719.

Ciruela F.; Burgueño J.; Casado V., Canals M.; Marcellino D.; Goldberg S.R.; Bader M.; Fuxe K.; Agnati L.F.; Lluis C.; Franco R.; Ferre S.; Woods A.S. Combining Mass Spectrometry and Pull-Down Techniques for the Study of Receptor Heteromerization. Direct Epitope-Epitope Electrostatic Interactions between Adenosine A2A and Dopamine D2 Receptors. Analytical Chemistry 2004,  76 5354 - 5363

Agnati L.F.; Leo G.; Vergoni A.V.; Martínez E.; Hockemeyer J.; Lluis C.; Franco R. Fuxe K.; Ferré S. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinsonís disease. Brain Research Bulletin 2004, 64 155 - 164

Torvinen M.; Torri C.; Tombesi A.; Marcellino D.; Watson S.; Lluis C.; Franco R.; Fuxe K.; Agnati L.F. Trafficking of Adenosine A2A and Dopamine D2 Receptors. Journal of Molecular Neuroscience 2005, 25 191 - 200

Canals M.; Angulo E.; Casado V.; Canela E.; Mallol J.; Viñals F.; Staines W.; Tinner B.; Hillion J.; Agnati L.; Fuxe K.; Ferre S.; Lluis C.; Franco R. Molecular mechanisms involved in the adenosine A1 and A2A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary culture. Journal of Neurochemistry 2005, 92 337 - 348

Saura J., Angulo E., Ejarque E., Casado V., Tusell JM., Moratalla R., Chen JF., Schwarzschild MA., Lluis C., Franco R. and Serratosa J. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. Journal of Neurochemistry, 2005, 95, 919-929

Vendrell M., Ventura R., Ewenson A., Royo M., Albericio F. N-[Chloro(dimethylamino)methylene]-N-methylmethanaminium chloride (TMUCl Cl), the Reagent of Choice for the Solid-Phase Synthesis of Anilides.  Tetrahedron Letters, 2005, 46, 5383-5386.         

Franco R.; Canals M.; Marcellino D.; Ferré S.; Agnati L.; Mallol J.; Casadó V.; Ciruela F.; Fuxe K.; Lluís C.; Canela E.I. Regulation of heptaspanning membrane-receptor function by dimerization and clustering. Trends in Biochemical Sciences 2003, 285,  238 -243

Franco F., Ciruela V., Casadó A., Cortes E. I., Canela J., Mallol L. F, Agnati S., Ferré Kj., Fuxe, and C. Lluis. Partners for Adenosine A1 Receptors. Journal of Molecular Neuroscience 2005, 26 221 - 231

Receptor-Receptor Interactions Among Heptaspanning Membrane Receptors: From Structure to Function Journal of Molecular Neuroscience Volume 26 Nos. 2-3, 2005

Torvinen M., Marcellino D., Canals M.,  Agnati L.F., Lluis C.,  Franco R.,  Fuxe K. Adenosine A2A Receptor and Dopamine D3 Receptor Interactions: Evidence of Functional A2A/D3 Heteromeric Complexes Molecular Pharmacology Vol. 67, No. 2

Ciruela, L. Canela, J. Burgueño, A. Soriguera, N. Cabello, E. I. Canela, V. Casadó, A. Cortés, J. Mallol, A. S.Woods, S. Ferré, C. Lluis, and R. Franco Heptaspanning Membrane Receptors and Cytoskeletal/Scaffolding Proteins. Journal of Molecular Neuroscience 2005, 26 277 - 292

Franco, R.; Casadó, V.; Mallol,J.; Ferré, S.; Fuxe, K.; Cortés, A.; Ciruela, F.; Lluis, C.; Canela, E.I. Dimer-based model for heptaspanning membrane receptors. Trends in Biochemical Sciences 2005, 300 7 360 - 366

Burgueño J.,  Enrich C.,  Canela E. I. , Mallol J., Lluis C.,  Ciruela F.,   Franco R. Metabotropic glutamate type 1 α receptor localizes in low-density caveolin-rich plasma membrane fractions  Journal of Neurochemistry, 2003, 86, 785-791

Dr   Lluïsa Garcia Esteve

Garcia-Esteve Ll., Navarro P., Ascaso C., Aguado J., Torres A. Major Depressive Episode in Postpartum: A Preliminary Prospective 1-Year Naturalistic Follow-Up. In New Research on Postpartum Depression. Editor Columbus F. Nova Science Publishers, Inc. (in press)

Dr  Andrés García Siso

García Siso A., Albadalejo Ribera C. Vulnerabilidad al trastorno mental en hijos de padres que padecen un Trastorno Mental Severo (TMS). Revista de Psicopatología y Salud Mental del niño y del Adolescente. Monográfico 1. Junio 2006; pp.47-61.

Dr  Mauro García Toro

Garcia-Toro M., Salvà J., Daumal J., Andrés J., Romera M., Lafau O., Echevarría M., Mestre M., Bosch C., Collado C.et al. High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression. Psychiatry Research: Neuroimaging, Vol. 146, No. 1, Pages 53-57, 2006. Garcia-Toro M., Salvà J. Transcranial Magnetic Stimulation in psychiatry. A decade balance of clinical investigation. Brain Pharmacology. 2002; 1: 225-228.

Dr  Ernest Giralt Lledó

Belda l., Llora X., Martinell M., Tarragó T., Giralt E. (2004) Computer-Aided Peptide Evolution for Virtual Drug Designo IV Jornades de Recerca en Enginyeria Biomedica (JEBC'04), Barcelona.

Belda l., Llora X., Martínell M., Tarragó T., Giralt E. (2004) Computer-Aided Peptide Evolution for Virtual Drug Design. Proceedings of the Genetic and Evolutionary Computation Conference (GECCO2004). Springer-Verlag. Lecture Notes in Computer Science No. 3103, p. 321-332. llliGAL, no. 20040150

Belda l., Llora X., Giralt E. (2005) Evolutionary algorithms and de novo peptide designo Soft Computing - A Fusion of Foundations, Methodologies and Applications (in press)

Belda l., Llora X., Martinell M., Tarragó T., Piqueras MG., Nicolas E., Giralt E. (2005) ENPDA:An evolutionary structure-based de novo peptide desígn algorithm. Journal of Computer-Aided. Molecular Design, 2005. 19:585-601.

Belda l., Traus lo, Llora X., Giralt E. (2005) Machine-learning tools for predicting docking energies in peptide-protein interactions. Journal of Chemicallnformation and Computer Sciences (in press).

Tarragó T., Sabidó, E., Kogan, M.J., de Oliveira, E., Giralt, E. (2005) Structural modeling and recombinant expression of human brain prolyl olígopeptidase, an important therapeutic target in the treatment of europsychiatric diseases (in press).

Teixidó M., Belda l., Zurita E., Llora X., Fabre M., Vilaró S., Albericio A., Giralt E. (2005) Evolutionary combinatorial chemistry, a novel tool for SAR studies on peptide transport across the blood-brain barrier. 2. Design, synthesis and evaluation of a first generation of peptides (in press).

Dr Maria Pilar Gual Garcia

Dr   Araceli Gila Castro

Dr  Salvador Cervera Enguix

 

Castro J.; Gila A.; Gual P.; Saura B.; Toro,J. Perfectionism dimensions in children and adolescents with anorexia nervosa. J Adolesc Health. 2004, 53: 392-398.

Dr  Diego Haro Bautista

Dr  Amadeu Llebaria Soldevila

Dr  Jesús Balsinde Rodriguez

Balboa, M. A. & Balsinde, J.  Involvement of calcium-independent phospholipase A2 in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. J. Biol. Chem. 277: 40384- 40389. (2002)

Balsinde, J., Winstead, M. V. & Dennis, E. A.  Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett. 531: 2-6. (2002)

Balboa, M. A., Sáez, Y. & Balsinde, J. Calcium-independent phospholipase A2 is required for Iysozyme secretion in U937 promonocytes. J. Immunol. 170: 5276-5280. (2003) 

Balboa, M. A., Pérez, R. & Balsinde, J. Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A2 is regulated by cytosolic phospholipase A2-derived hydroperoxyeicosatetraenoic acid. J. immunol. 171: 989-994. (2003)

Fuentes, L., Pérez, R., Nieto, M. L., Balsinde, J. & Balboa, M. A.  Bromoenollactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A2. J. Biol. Chem. 278: 44683-44690. (2003)

Pérez R., Melero R., Balboa M. A. & Balsinde J. (2004) Role of group VIA calcium-independent phospholipase A2 in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937cells responding to hydrogen peroxide. J. Biol. Chem. 279: 40385-40391.

Balsinde J. & Balboa M. A. (2005) Cellular regulation and proposed biological functions of group VIA phospholipase A2 in activated cells. Cell. Signal. 17: 1052-1062.

Pérez R., Matabosch X., Llebaria A., Balboa M. A., & Balsinde J. (2005)  Blockade of arachidonic acid Incorporation into phospholipids induces apoptosis in U937 promonocytic cells. J. Lipid Res. 47: 484-491.

 

Dr  Antonio Labad Alquézar

Gutiérrez-Zotes JA., Bayón C., Montserrat C., Valero J., Labad A., Cloninger R., Fernández-Aranda F. Inventario del Temperamento y el Carácter- Revisado (TCI-R). Baremación y datos normativos en una muestra de población general. Actas Esp Psiquiatr 2004: 32 (1): 8-15

Gutiérrez-Zotes JA., Cortés MJ., Valero J., Peña J., Labad A Propiedades psicométricas de la versión española abreviada del TCI-R (TCI-140) y su relación con las Escalas de la personalidad Psicopatológica (MMPI-2 PSY-5) en pacientes. Actas Esp Psiquiatr 2005: 33(4) 231-237.

Mulet B., Valero J., Gutiérrez-Zotes JA., Montserrat, C., Cortés MJ., Jariod, M., Martorell, L., Vilella, E., Labad, A Sustained and selective attention in patients with schizophrenia or other psychoses and in their first- degree relatives. (in revision at European Psychiatry).

Cortés MJ., Valero J., Gutiérrez-Zotes JA., Mulet B., Jariod M., Pérez M., Martorell L., Vilella E., Labad A. Psychopathology and personality traits in psychotic patients and their first-degree relatives (in revision at  Schizophrenia Research).

Valero J., Gutiérrez-Zotes A., Pérez M., Jariod M.,Mulet B., Cortés MJ., Martorell L., Vilella E., Labad A. Psychiatric symptoms in psychotic patients and their first-degree relatives (in revision at  Journal of Psychiatry and Neuroscience).

Martorell L., Valero J., Mulet B., Gutiérrez-Zotes A., Cortés MJ., Jariod M., Pérez M., Labad A.Vilella E. M129V variation in the prion protein gene and psychotic disorders: relationship to neuropsychological and psychopathological measures (in revision at  Journal of Psychiatric Research).

Vilella E., Costas J., Sanjuan J., Guitart M., De Diego Y., Carracedo A., Martorell L., Valero J., Labad A., De Frutos R., Nájera C., Moltó MD., Toirac I., Guillamat R., Brunet A., Vallés V., Pérez L., Leon M., Rodríguez de Fonseca F., Philips C., Torres. M. A case-control study with the schizophrenia candidate genes D-amino acid oxidase, D-amino acid oxidase activator, dysbindin, neuregulin 1 and regulator of G-protein signaling 4 and lack of genetic interaction between them (in revision at American Journal of Psychiatry)

Dr   Luisa Lázaro García

Lázaro L., Bargalló N., Castro-Fornieles J., Falcón C., Andrés S., Calvo R., Junqué C . Brain changes in children and adolescents obsessive-compulsive disorder before and after treatment: A voxel-based morphometric MRI study. (in revision)

Lázaro L., Bargalló N., Castro-Fornieles J., Andrés S., Falcón C., Junqué C. Single-voxel proton magnetic resonante spectroscopy in pediatric obssesive-compulsive disorder befote and alter treatment. (in preparation)

Lázaro L., Junqué C., Caldú X., Bargalló N., Andrés S., Falcón C., Morer A., Castro-Fornieles J. Activacion cerebral in children and adolescents with obsessive-compulsive disorder before and after treatment: A functional MRI study. (in preparation) 

Dr  M. Teresa Lluch Canut

Lluch MT., Checa F., García J., Márquez MI, Camarena X., Beltrán JJ., Ayllón L., Sabadell M., Alonso M., Díaz T., Martínez S., Rigol A., Sabater MP. Efectividad de la Atención Domiciliaria de Enfermería administrada a pacientes con Trastorno Mental Severo (TMS): Ensayo Clínico Controlado. Enfermería Clínica (in press).

Dr  Francisco Juan Lomeña Caballero

Mateos JJ., Lomena F., Parellada E., Font M., Fernandez E., Pavia J., Prats A., Pons F., Bernardo M. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. M Psychopharmacology, 2005; 181(2):401-6.

Mateos JJ., Lomena F., Parellada E., Font M., Fernandez E., Pavia J., Prats A., Bernardo M. Disminución del transportador de dopamina estriatal en primeros episodios psicóticos de pacientes esquizofrénicos tratados con risperidona. Rev Esp Med Nucl, 2006; 25 (3): 159-165.

Dr  Rafael Maldonado López

Dr  Emilio Fernández Espejo

Dr  Ferran Sanz Carreras

Dr  María Isabel Loza García

González-Gómez JC., Santana L., Uriarte E., Brea J., Villazón M., Loza M.I, De Luca M., Rivas ME., Montenegro GY., Fontenla JA. New arylpiperazine derivatives with high affinity for. 1A, D2 and 5-HT 2A receptors. Bioorg and Med Chem Lett 2003; 13:175-178

J Brea, C F. Masaguer , M Villazón, M. I Cadavid , E Raviña, F Fontaine, C Dezi, M Pastor, F Sanz c, M. I Loza. Conformationally constrained butyrophenones as new pharmacological tools fo study 5- HT 2A and 5- HT 2C receptor behaviours. European Journal of Medicinal Chemistry 38 (2003) 433-440

F Fontaine, M Pastor, F Sanz. Incorporating Molecular Shape into the Alignment-free GRid-Independent Descriptors J. Med. Chem. 2004, 47; 2805-2815.

Brea J., Masaguer Cf., Villazón M., Cadavid MI., Raviña E., Fontaine F., Dezi C., Pastor M., Sanz F., Loza MI. Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT 2A and 5-HT 2C receptor behaviours. Eur J Med Chem. (in press)

Enguix MJ., Sánchez L., Villazón M., Brea J., Tristán H., Caruncho HJ., Cadavid MI., Loza MI. Differential regulation of. rat peripheral 5-HT 2A and 5-HT28 receptor systems:influence of drug treatment. Naunyn-Schmiedeberg's Arch Pharmacol. 2003; 368:79-90.

Fernandez Espejo E., Galán Rodríguez B. Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology. 175: 220-224, 2004.

Alvarado M., Coelho A., Masaguer CF., Raviña E., Brea J., Padín JF., Loza MI. Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics. Bioorganic & Medicinal Chemistry Letters 2005.  (in press)

Brea J., Castro M., Loza MI., Masaguer CF., Raviña E., Dezi C., Pastor M., Sanz F., Cabrero A., Galán-Rodríguez B., Fernández-Espejo E., Maldonado R. and Robledo P. 2006. QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology, (in press)

Brea J., Cadavid MI., Villazón M., Quintián F., Padín JF., López-Gimènez JF., Vilaró MT., Mengod G., Berg KA., Clarke WP., Loza MI. Different active status of human 5-HT2A receptors at PLA2, but not PLC, signalling pathway. Cellular Sognalling (sent)

Brea J., Castro M., Cadavid MI., Domínguez E., Dezi C., Pastor M., Sanz F., Espejo E., Maldonado R., Robledo P., Loza MI. Multivariate analysis of in vitro and in vivo potency of new butyrophenones as new antipsychotics. (in preparation)

Caro Y., Torrado M., Masaguer CF., Raviña E., Padín F., Brea J., Loza MI. Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics. Bioorg and Med Chem Lett 2004; 14:585-589

Dezi C., Pastor M., Sanz F. Homology modelling and docking studies of the 5-HT2A and 5-HT2C receptors. (sent)

Fontaine F., Pastor M., Zamora I., Sanz F. Anchor-GRIND: Filling the Gap between Standard 3D QSAR and the GRid-INdependent Descriptors. J Med Chem 2005; 48: 2687-94.

Padín JF., Castro MA., Iglesias R., Brea J., Loza MI. PLC and PLA2 signal transduction pathways mediating functional response to serotonin in human platelets. (in preparation)

Robledo P., Balerio G., Berrendero F. and Maldonado R. 2004. Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 369: 338-349.

Robledo P., Mendizábal V., Ortuño J., de la Torre R., Kieffer BL., and Maldonado R. 2004. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. Eur J Neurosci., 20: 853-858.

Trigo JM., Panayi F., Soria G., Maldonado R. and Robledo P. 2006. A reliable model of intravenous MDMA self-administration in naïve mice. Psychopharmacology, 184: 212-20.

Villazón M., Enguix MJ., Tristán H., Honrubia MA., Brea J., Maayani S., Cadavid MI., Loza MI. Different pharmacological properties of two equipotent antagonists (clozapine and rauwolscine) for 5-HT2B receptors in rat stomach fundus. Biochem Pharmacol. 2003; 66:927-937.

Villazón M., Padín JF., Cadavid MI., Enguix M., Tristán H., Orallo F., Loza MI. Functional Characterization of Serotonin Receptors in Rat Isolated Aorta. Biological and Pharmaceutical Bulletin 2002; 25(5):584-590.

Dezi C., Fontaine F., Pastor M., Sanz F. Consensus Approaches Using SBDD and 3D-QSAR. A Practical Example on a Series of 5-HT2A/2C Ligands (sent)

Brea J., Castro M., Loza M.I., Masaguer, Raviña E., Dezi C., Pastor M., Sanz F., Cabrero A., Galán-Rodríguez B., Fernández-Espejo E., Maldonado R., Robledo P. 2-[4-(6-fluorobenzisoxazol-3-yl)piperidinyl]methyl-1,2,3,4-tetrahydrocarbazol-4-one, a new clozapine-like lead with atypical antipsychotic profile: synthesis, molecular modeling, and In vitro and In VIVO Pharmacological profiling J Med Chem (sent)

Quintián F., Brea J., Masaguer C.F., Raviña Cadavid M.I., Loza M.I. New inverse agonists at 5-HT2C  receptors with putative atypical antipsychotic activity. XXV Congreso de la Sociedad Española de Farmacología, Cádiz 2003 "Methods and Find Exp Pharmacol 2003; 25 (Suppl A) : P -19 .

Quintián F., Brea J., Masaguer C.F., Raviña Cadavid M.I., Loza M.I. Newpharmacological tools to study 5-HT2A receptors conformation behaviours.  XXV Congreso de la Sociedad Española de Farmacología, Cádiz 2003 "Methods and Find Exp Pharmacol 2003; 25 (Suppl A) : C 04 .

Raviña E., Masaguer C.F., Loza M.I., Cadavid M.I., Brea J., Dezi C., Pastor M., Sanz F. Conformationally constrained amin#,tyrophenones as new T2 ligands. Synthesis, molecular modelling and assays antagonists and inverse agonists. Drugs Future 2002, 27 (p.45). XVllth International Symposium Medicinal Chemistry. Barcelona, 1-5 de septiembre, 2002. Comunicación oral.

Domínguez E., Padín F., Buceta M., Rodríguez M.A., Loza M.I., Cadavid M.I. Comparative study of the regulation produced by olanzapine in 5-HT2A and D3 central and peripheric sites. XXV Congreso de la S ledad Española Farmacología, Cádiz 2003: Methods and Find Exp Pharmacol 2003; 25 (Sup A): P-26

Brea J., Quintian F., Raviña E., Cadavid M.I., Loza M.I. Are different 5-HT2A conformations mediating the same signalling pathway? 4th  Congress of he Federation of the European Pharmacological Societies (EPHAR). Porto (Portugal) 2004, July 14-17. Poster (P 05.05). Fundamental & Clinical Pharmacology. Volumen 18, Suppl. 1, July 2004.

Raviña E., Masaguer C.F., Brea J., Loza M.I. Conformationally constrained azabutyrophenones as potencial atypical antipsychotics. XVth International Symposium on Medicinal Chemestry. Copenhagen, Denmark & Malmö, Sweden 2004, August 15-19. Poster (P-162). Drugs or the Future. Volume 29, Suppl. A, August 2004

Quintian F., Brea J., Masaguer C.F., Raviña E. Loza M.I. New tools with structural and pharmacological homology usefulf for defining functional conformational populations of 5-HT2C and 5-HT2A receptor. XXVI Congress of the Spanish Society of Pharmacology Salamanca (Spain) 2004, September 26-29. Poster (P-051). Methods and Findings in a Experimental and Clinical Pharmacology. Volumen 26. Suppl. ArlO04.

Dr  Teodor Marcos Bars

M.J.Portella y T.Marcos. Implicación del lóbulo frontal en la depresión mayor senil. Revista de Neurologia, 2002; 35 (9);891-894.

M. J. Portella, T. Marcos, L. Rami, V. Navarro, C. Gastó and M. Salamerol. Residual cognitive impairment in late-life depression after a 12-month penad follow-up. lnt. J. Geriatr Psychiatry 2003; 18: 571-576

M.J. Portella,T. Marcos-Bars ,L. Rami-González, V. Navarro-Odriozola, C. Gastó-Ferrer, M Salamero. Torre de Londres': planificación mental, validez y efecto techo 2003, Rev.Neurol 2003;37(3):210-213

Marcos T., Portella MJ., Navarro V., Gastó C., Rami L., Lázaro L., Salamero M. Neuropsychological prediction of recovery in late-onset major depression. Int J Geriatr Psychiatry 2005; 20:790-795. / Int J Geriatr Psychiatry 2005; 20:1-6.

Dr  Concepció Marin Agustin

Saldaña M., Bonastre M., Aguilar E., Marin C. B p50 and p65 subunits Role of nigral NF expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats. Eur. Neuropsychopharmacol. 2006. (in press)

Saldaña M., Aguilar E., Bonastre M., Marin C. Differential nigral expression of Bcl-2 protein family in chronically haloperidol and clozapine-treated rats: role in neurotoxicity and stereotyped behavior. Exp. Neurol. (in revision)

Saldaña M., Aguilar E., Bonastre M., Marin C. Striatal and nigral expression of the cyclooxigenase-2 (Cox-2) in an experimental model of tardive dyskinesia. (in preparation)

Saldaña M., Bonastre M., Aguilar E., Marin C. Expresión del factor de transcripción NFkB en un modelo experimental de discinesia tardía. Neurología 2004; 19: 569. LVI Reunión Anual de la Sociedad Española de Neurología, Barcelona, Novembre 2004

Saldaña M., Bonastre M., Aguilar E., Marin C. Effect of typical and atypical neuroleptics on nigral NFkB expression in an experimental model of tardive dyskinesia. Mov Dis 2005; 20 (Suppl 10): S15. 9th International Congress of Parkinson's disease and Movement Disorders, New Orleans, EEUU, Març 2005.

Dr  Josep Manuel Menchón Magriñà

Pujol J., Soriano-Mas C., Alonso P., Cardoner N., Vallejo J., Deus J., Menchón JM. Mapping structural brain alterations ín obsessive-compulsive disorder. Archives of General Psychiatry 2004; 61 :720-730.

Alonso P., Menchon JM., Mataix-Cols D., Pifarre J., Urretavizcaya M., Crespo JM., Vallejo G., Vallejo J. Perceived parental rearing style in Obsessive-Compulsive Disorder: Relation to symptom dimensíons. Psychiatry Research 2004; 127:267.278.

Labad J., Menchón JM., Alonso P., Segalas C., Jiménez S., Vallejo J. Female reproductive cycle and obsessive-compulsive dísorder. Journal of Clínical Psychiatry, 2005;66

Labad J,. Menchon JM., Alonso P., Segalas C., Jimenez S., Jaurrieta N., Leckman JF., Vallejo J. Gender differences in obsessive-compulsive dimensions. (submitted)

Alonso P., Menchón JM., Jiménez S., Segalàs J., Mataix-Cols D., Jaurrieta N., Vallejo J., Cardoner N., Pujol J. Personality dimensions in obsessive-compulsive disorder: relation with clinical variables. (submitted)

Dr  Guadalupe Mengod Los Arcos

Dr  Francesc Pérez Arnau

Amargós-Bosch M, Bortolozzi A, Puig V, Serrats J, Adell A, Celada P, Toth M, Mengod G, and Artigas F. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cerebral Cortex. 14 (2004): 281-299.

De Almeida J. and Mengod G. Serotonin 5-HT2A receptors are prefferentially expressed by glutamatergic neurons in the human and monkey prefrontal cortex. (sent)

De Almeida J. and Mengod G. Glutamatergic neurons but not GABAergic interneurons express 5-HT1A receptors in the human and monkey prefrontal cortex. (in preparation)

Santana N., Bortolozzi A., Serrats J., Mengod G., and Artigas F (2004) Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100-1109.

Dr  Rafael Artuch Iriberri

Ormazabal A., Artuch R., Vilaseca MA., Aracil A., Pineda M. Cerebrospinal fluid concentrations of folate, biogenic amines and pterins in Rett syndrome: treatment with folinic acid. Neuropediatrics 2005; 36:380-385.

Ormazabal A., Vilaseca MA., Pérez-Dueñas B., Lambruschini N., Gómez L., Campistol .J, Artuch R. Platelet serotonin concentrations in PKU patients under dietary control and tetrahydrobiopterin treatment. J Inherit Metab Dis 2005: 28-863-870.

Poo-Arguelles P., Arias A., Vilaseca MA., Ribes A., Artuch R., Sans-Fito A., Moreno A., Jakobs C., Salomons G.  X-Linked creatine transporter deficiency in two patients with severe mental retardation and autism. J Inherit Metab Dis. 2006;29(1):220-3.

Arias A., Vilaseca MA., Artuch R., Ribes A., Campistol J. Diagnóstico y tratamiento de los sindromes de deficiencia de creatina cerebral. Rev Neurol 2006 (in press).

Ragione FD., Tiunova A., Vacca M., Strazzullo M., González E., Armstrong J., Valero R., C, Pineda M, Hulten M, Monros E, D'Esposito M, Prokhortchuk

E. The x-linked methyl binding protein gene kaiso is highly expressed in brain but is not mutated in rett syndrome patients. Gene 2006 Mar 10; PMID: 16530985. 

Arias A., Ormazabal A., Moreno J., Gonzalez B., Vilaseca MA., Garcia-Villoria J., Pampols T., Briones P., Artuch R., Ribes A. Methods for the diagnosis of creatine deficiency syndromes: A comparative study. J Neurosci Methods. 2006 Apr 16; [Epub ahead of print] PMID: 16621013 [PubMed - as supplied by publisher]

Ormazabal A., Garcia-Cazorla A., Perez-Duenas B., Gonzalez V., Fernandez-Alvarez E., Pineda M., Campistol J., Artuch R. Determination of 5-methyltetrahydrofolate in cerebrospinal fluid of paediatric patients: Reference values for a paediatric population. Clin Chim Acta. 2006 Apr 17; [Epub ahead of print] PMID: 16624264

Dr  Jordi Obiols Llandrich

Obiols J.E. y Barrantes N. (2002). Evaluación psicobiológica de la pre-esquizofrenia. Informaciones psiquiátricas, 168 (2): 217-224.

Llebaría G., Prats E., Vicens-Vilanova J. y Obiols J.E. (2003). Preferencia manual en el espectro esquizofrénico. Revista de Psicopatología y Psicología Clínica, 8(3): 189-198.

Martinena P., Medina C., Baños I., Sabanés A., Navarro B., Vicens-Vilanova J., Álvarez E.M., Barrantes-Vidal N., Subirá S., Obiols J.E. 2006. Esquizotipia y memoria verbal en población general adolescente. Psicothema, Vol.18. (in press).

Barrantes-Vidal N., Kwapil T.R., Navarro B., Vicens-Vilanova J., Subirà S., Obiols J.E. Mixed- and ambiguous-handedness are differentially related with the dimensions of schizotypy in a general population sample.  Schizophrenia Research. (submitted).

Vicens-Vilanova J., Martinena P., Arias J., Vallez M., Navarro J.B., Obiols J.E., Subirà S. ¿Están los déficit en la teoría de la mente  relacionados con las alteraciones cognitivas en los pacientes con esquizofrenia crónica? Internacional Journal of Cognitive Psychiatry. (submitted).

Medina C., Navarro J.B., Martinena P., Baños I., Vicens-Vilanova J., Barrantes-Vidal N., Subirá S., Obiols J.E. Evaluación de la conducta adolescente con las escalas de Achenbach: ¿Hay concordancia entre informantes? Salud Mental. (submitted).

Medina C., Navarro J.B., Martinena P., Baños I., Vicens-Vilanova J., Barrantes-Vidal N., Subirá S., Obiols J.E.¿Explica la esquizotipia la discordancia entre informantes de alteraciones conductuales adolescentes? Salud Mental. (submitted).

Baños I., Navarro J.B., Medina C., Martinena P., Vicens-Vilanova J., Subirà S., Barrantes-Vidal N., Obiols J.E. Características dimensionales de la esquizotipia en adolescentes de la población general. International Journal of Clinical and Health Psychology. (submitted).

Barrantes-Vidal N., Vicens-Vilanova J., Subirà S., Obiols J.E. (2002). Handedness and schizotypy in an adolescent community sample. Acta Psychiatrica Scandinavica, 413(106), Suppl., 79.

Barrantes-Vidal N., Vicens-Vilanova J., Subirà S., Obiols J.E. (2002). Gender and schizotypy in community adolescents. Acta Psychiatrica Scandinavica, 413(106), Suppl., 30.

Obiols J.E. y Pousa E. (2004). Orígenes y aplicaciones de la teoría de la mente. Actas Españolas de Psiquiatría, 31: núm. Extraordinario 1, 145.

Dr  Eduard Parellada Rodón

Font M., Parellada E., Fernández-Egea E., Bernardo M., Lomeña F. Neuroimagen funcional de las alucinaciones auditivas en la esquizofrenia. Actas Españolas de Psiquiatría 2003; 31(1):3-9.  Article de revisió:

Parellada E., Lomeña F., Font M., Pareto D., Gutierrez F., Simó M., Fernández- Egea E., Pavía J., Ros D., Bernardo M. Auditory hallucinations in first episode schizophrenic patients: a PET study during hallucinatory state, after remission and during linguistic auditory activation. Brain 2006 (submitted)

Parellada E., Bernardo M., Lomeña F., Font M., Fernández-Egea E. Neuroimagen funcional del fenómeno alucinatorio. En Pichot P, Ezcurra J, González-Pinto A, Gutiérrez Fraile M (eds): Intervención en crisis y tratamiento agudo de los trastornos psiquiátricos graves. Madrid: Ediciones Grupo Aula Médica, 2003; 343-351.

Parellada E., Bernardo M., Crespo-Facorro B., Arango C. Esquizofrenia. Neuroimagen Funcional. En: C Arango, B Crespo-Facorro, M Bernardo (eds): Neuroimagen en Psiquiatría. Barcelona: Psiquiatría Editores, 2003; 131-148.

Dr  Lluís San Molina

Dr  Ignasi Carrió Gasset

Arranz B., Rosel P., Ramírez N., Dueñas MR., Fernandez P., Sanchez JM., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in antipsychotic-free and not in naive first-episode schizophrenic patients. J Clin Psychiatry 65 : 1335-1342 (2004)

Dueñas MR., Aleu M., González I., San L., Salavert J., Arranz B. Impact of medical counseling to quit smoking during the process of deshabituation in patients with mental illness. Actas Esp Psiquiatria 32(5): 287-292 (2004)

Rosel P., Arranz B., Urretavizcaya M., Oros M., San L., Navarro MA. Brain serotonin 5-HT2A and 5-HT 4 postsynaptic receptors and their intracellular signalling systems IP3 and cAMP in depressed violent suicide Victims. Neuropsychobiology 49: 189-195 (2004).

Templeman LA., Reynolds GP., Arranz B., San L. CPolymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-Cindiced weight gain in Caucasian subjects with a first-episode psychosis Pharmacogenetics,  (2005); 15:195-200

Reynolds GP., Arranz B., Templeman LA., Fertuzinhos S., San L. Negative and depressive symptom response to antipsychotic treatment of drug-naïve psychotic patients is predicted by a 5-HT1A receptor gene polymorphism.  Am J Psychiatry; 2006 (accepted)

Arranz B., San L., Dueñas RM., Centeno M., Ramirez N., Salavert J., del Moral E. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. J Clin Psychiatry (sent)

Perez V., Catafau AM., Corripio I., Martin JC., Alvarez E. Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(5):767-70

Corripio I., Perez V., Catafau AM., Mena E., Carrio I., Alvarez E. Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neuroimage 2006; 29(2):662-666.

Catafau AM., Corripio I., Pérez V., Martin JC., Schotte A., Carrió I., Alvarez E. Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response. Psychiatry Res Neuroimaging; 2006(accepted)

Ramirez N., Arranz B., Martín C., San L. Combined use of platelet serotonergic markers and psychopathological scales as diagnostic screening of a psychotic versus a depressive disorder. Eur Psychiatry 2003; 18(7): 369-371

Ramírez N., Arranz B., Sánchez JM, Centeno M., San L. Depression in Schizophrenia, Can it be Treated? A Review of the Evidence. Curr Psychiatry Revi, 2006 (accepted)

Reynolds G.P.,  Arranz B.,  Templeman L.A., Fertuzinhos S.,  San, L. Effect of 5-HT1A Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients Psychiatry 2006; 163:1826-1829

Dr  Eduardo Soriano Garcia

Dr  Héctor Juan Caruncho Michinel

Carmona, M.A.-, Martínez, A., Soler, A., Blasi, J., Soriano, E. and Aguado, F. Ca2+ -Evoked synaptic transmission and neurotransmitter receptor levels are impaired in the forebrain of trkB(-/-) mice. Molecular and Cellular Neuroscience, (2003), 22: 210-226.

Pascual, M., Pozas, E. and Soriano E. Role of class 3 semaphorins in the development and maturation of the septohippocampal pathway. Hippocampus, (2005), 15 (2) 184-202

García-Frigola, C., Burgaya, F., Calbet, M., de Lecea, L.,and Soriano, E. A collection of cDNAs enriched in upper corticallayers 01 the mouse embryo. Molecular Brain Research (2004) 122:133-150

González-Guillault, C., Del Río, J .A., Urefia, J .M., Jiménez, E.M., Barallobre, M.J., Wandosell, F., Pascual, M., Simó, S., Pujades, LL., Latorre, A., Tessier-Lavigne, M., CUrTan, T., Soriano, E. and Avila, J. MAP1B is requiredlor reelin and netrin 1 signaling in neuronal migration and axonal guidance. Current Biology (2004), 25;840-850

Alcanttara, S., Martínez-López, M. J., Mascaró, C., Ruiz-Lozano, P., Maes, T., Soriano, E. and Buesa, C. Mouse Navigator-l is a microtubule binding protein essentia for neuritogenesis and neural migration. Neuron, (2003), (submitted)

HJ. Caruncho. Differentifil regulation of rat peripheral 5-HT2A y 5-HT2B receptor systems: influence of drug treatment. Naunyn-Schmid. Arch. Pharmacol. 368:79-90. Enguix et al. (2003)

González-Guillault C., Del Río J.A., Ureña J.M., Jiménez E.M., Barallobre,M.J.,.Pascual M., Simó S., Pujades LL., Latorre A., Wandosell F., Soriano E. and Avila J. A role of MAP1B in Reelin-dependet Neuronal Migration. Cerebral Cortex, (2005), 15(8):1134-45.

Botella-López A., Gavín R., García-Ayllón MS., Gómez-Tortosa E., Blesa R., Soriano E. and Sáez-Valero J. Reelin in the cerebrospinal fluid and plasma of subjects with neurological diseases PNAS (2006) (in press).

Caruncho H.J., Dopeso-Reyes IG., Loza MI, Rodríguez MA. GABA, reelin and the developmental hypotesis of schizophrenia. Critical Reviews in Neurobiology, (2004), 16:25-32

Dr Lauro Sumoy Van Duck

Carim- Todd L, Estivill X, Sumoy L. LERN1, a novelleucine-rich repeat protein with specific expresión in the limbic system". Am. J. Hum. Genetics 73(Supplement):p342, abstract n° 1004. (2003)

Carim- Todd L, Escarceller M, Estivill X, Sumoy L. LRRN6A/LERN1 (Leucine- rich Repeat Neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex. European Journal Neuroscience 18:3167-3182. (2003)

Sumoy L., Carim- Todd Lo, Parra G., Andreu N, Escarceller M, Pluvinet R., Armengol LL.; Guigó R., Estivill X. Annotated transcript map of human chromosomal region 15q24-q26. Candidate genes for panic and anxiety syndrome and joint laxity. (in preparation)

Sumoy L., Carim-Todd L, Parra G, Andreu N, Escarceller M, Pluvinet R., Armengol LL.; Guigó R., Estivill X. Annotated transcript map of human chromosomal region 15q24-q26. Candidate genes for panic and anxiety syndrome and joint laxityl. (in preparation)

Carim- Todd L., Escarceller M., Estivill X., Sumoy L. LERN1, a membrane protein with LRR domains which interacts with Myt1L/NZF1 in limbic system neurons with a potential role in panic disorder. (in preparation)

Dr   Jorge Tizón García

Tizón JL. Prevención e intervención en la salud mental de la primera infancia desde los dispositivos de Atención Primaria. Pediatría de Atención Primaria 2002; 13,4: 81-107.

Tizón JL., Buitrago F., Ciurana R. (Coordinador), Chocrón L., Fernández C., Garcia-Campayo J., Montón C., Redondo MJ. Prevención de los trastornos de la salud mental desde la atención primaria de salud. El Programa del PAPPS y la SEMFyC, versión 2003. En www.papps.org/recomendaciones/2003/saludmental.pdf (página del Programa de Actividades Preventivas y de Promoción de la Salud y de la Sociedad Española de Medicina de Familia y Comunitaria).

Tizón JL. Infancia, Migraciones y Salud Mental. Revista Associació Catalana d'Atenció Precoç 2003; 21-22:47-73.

Tizón JL., Artigue J., Gomà M., Parra B., Marzari B. La observación de bebés en una Unidad Funcional de Atención a la Salud Mental de la primera infancia (UFAPI). Cuadernos de Psiquiatria y psicoterapia del niño y del adolescente 2004;37/38: 85-112.

Tizón JL. ¿Se puede pensar todavía en una "sociogénesis" y en una "psicogénesis" de las psicosis?. Archivos de Psiquiatría 2004;67(1): 67-72.

Artigue, J., Tizón, J.L., Parra B. et al. Una aproximación a la detección precoz de los trastornos mentales graves. Revista de Psicopatologia y Salud Mental del niño y del Adolescente. Barcelona 2004, 4: 51-67.

Tizón JL. Repercusiones sobre el niño de los trastornos mentales de sus progenitores y cuidadores. FMC (Formación Médica Continuada, Barcelona) 2005;12(4):220-236.

Tizón JL., Parra B., Artigue J., Ferrando J., Catalá L., Sorribes M., Pareja F., Perez C. Hijos de pacientes con psicosis en el Proyecto SASPE: Investigar para cuidar un futuro comprometido. Archivos de Psiquiatría 2006; 69(1): 47-68.

Tizón JL. Prevención de los trastornos de la salud mental en atención primaria. En C. Brotons, R. Ciurana, M. Iglesias (Editores). Manual de Prevención en Atención Primaria. Programa de Actividades Preventivas y de Promoción de la Salud (PAPPS). Barcelona: Sociedad Española de Medicina de Familia y Comunitaria 2003 (Versión CD. ISBN: 84-89045-35-6; DL: B-18.565-2003).(pp 547-574; 597-608 i 609-628).

Tizón JL., Fuster P. The father's role. En A. Gardziel & Esther Bick Associattion (dir.) Create Bonds. Kraków (Polonia): Wydawnictwo Radamsa 2004. (pp. 149-169).

Tizón JL. Introducción a la Prevención de los trastornos de la salud mental desde la Atención Primaria de Salud, versión 2003. En www.papps.org/recomendaciones /2003/saludmental.pdf (página del Programa de Actividades Preventivas y de Promoción de la Salud y de la Sociedad Española de Medicina de Familia y Comunitaria).

Tizón JL., Lemos J., Vallina J., Farriols N., Palma C., Artigue J. Early interventions in schizophrenic disorders: Some iberic experiences. Acta Psychiatrica Scandinavica. (Supplementum) 2006: 431 (114): 30-31.

Tizon JL., Artigue J., Parra B., Ferrando J., Català L., Pérez C., Pareja F. Risk factors of Psychoses: Is a preventive detection possible? Acta Psychiatrica Scandinavica. (Supplementum) 2006: 431 (114): 14.

Tizon JL., Artigue J., Parra B., Pérez C., Ferrando J. First results of the LISMEP: an approach to the early detection of severe mental disorders. Acta Psychiatrica Scandinavica. (Supplementum) 2006: 431 (114): 55.

Tizon JL., Ferrando J., Artigue J., Parra B., Pérez C., Pareja F. Psychosis And Marginal Neighborhoods, or "is the schizophrenia an genetically caused illness of the brain? Acta Psychiatrica Scandinavica. (Supplementum) 2006: 431 (114): 64.

Dr. Adolf Tobeña Pallarés

Facultat de Medicina. Universitat Autònoma de Barcelona

Giménez-Llort L., Cañete T., Guitart-Masip M., Fernández-Teruel A., Tobeña A. Two distinctive apomorphine-induced phenotypes in the Roman high - and low - avoidance rats. Physiology & Behavior 86 (2005) 458-466

Guitart M. (2003) Más allá de la hipótesis dopaminérgica: fisiopatologia de la esquizofrenia. Actualizaciones en Neurologia, Neurociencias y Envejecimiento, 1(5), 287-296.

Fernández Teruel A., Pérez M., Blázquez G., Aguilar R., Cañete T., Guitart M., Giménez Llort L. y  Tobeña A. (2005) Déficit del umbral de inhibición latente en las Ratas Romana de Alta Evitación: ¿Un modelo genético de anomalias atencionales de la esquizofrenia?. Actas Españolas de  Psiquiatria  (en premsa).

Fernández-Teruel A., Giménez-Llort L., Aguilar R.  y Tobeña A.  (2005), Modelos animales en Psiquiatria. en J. Vallejo y C. Leal (Eds): Tratado de Psiquiatria, Vol. I, Madrid: STM Editores (pp. 341-356).            

Guitart-Masip M., Giménez-Llort L., Fernández-Teruel A., Cañete T., Tobeña A.,  Ögren SO.,  Terenius L. and  Johansson  B. (2006) Reduced ethanol response in the alcohol-preferring RHA rats and neuropeptide mRNAs in relevant brain structures. European Journal of Neuroscience, 23, 531-540.

Guitart-Masip M., Johansson B., Cañete T., Fernández-Teruel A., Tobeña A., Giménez-Llort L. and Terenius L. (2006) Acute response to amphetamine does not predict vulnerability  to behavioural sensitization in the Roman rat strains: possible relation to regional transcripts levels. Journal of Neuroscience (sotmès).

Guitart-Masip M., Johansson B., Cañete T., Fernández-Teruel A., Tobeña A., Terenius L. and Giménez-Llort L. (2006) Distribution and quantification of Dopamine receptor subtypes and Darp-32 mRNA in the Roman strains: divergent anatomical pattern of binding. Neuroscience (sotmès).

López-Aumatell R., Blàzquez G., Giménez-Llort L., Gil L., Aguilar R., Tobeña A. and Fernández-Teruel A. (2006) Differences in fear-potentiated startle and classical fear conditioning beteween the Roman strains. Physiology and Behavior (sotmès).

Cañete A., Guitart M., Fernández-Teruel A., Tobeña A., Giménez-Llort L. (2003) Vulnerabilidad a las estereotipias en ratas Romanas-RHA: estudios con agonistas dopaminérgicos. Revista de Neurologia, 37 (12), 1178-9 (Proceedings SENC 2003-P247).

Cañete A., Guitart M., Fernandez Teruel A., Tobeña A., Giménez-Llort L. (2003) Apomorphine and amphetamine induce differential actvity/ stereotyped patterns in Roman High- and Low Avoidance rats. Acta Neurobiologia Experimentalis, 63, 55 (Abstracts of 35th EBBS Congress, PF5, Barcelona 17-20 Sept).   

Giménez-Llort L., Cañete A., Fernández-Teruel A., Tobeña A. (2003) La estimulación postnatal reduce la respuesta convulsiva y la mortalidad inducidas por NMDA en las cepas RHA/VERH-I y RLA/VERH-I. Revista de Neurologia, 37 (12), 1181-2 (Proceedings SENC 2003, P259).

Guitart-Masip M., Johansson B., Fernández-Teruel A., Cañete A., Tobeña A., Terenius L., Giménez-Llort L. Divergent anatomical pattern of d1 and d3 binding And dopamine- and cyclic amp-regulated phosphoprotein Of 32 kda mrna expression in the roman rat strains: Implications for drug addiction Neuroscience 142 (2006) 1231-1243

Dr  Marta Torrens Mèlich

Fonseca F., Martín-Santos R., Torrens M. Genética y dependencia de opiáceos. Adicciones 2005; 17 (supl 2): 57-80. 

Fonseca F., de Cid R., Gratacós M., de la Torre R.,  Martín-Santos R.,  Estivill X., Torrens M.  Personality traits and pharmacogenomics in opioid addicts non-responders to methadone maintenance treatment: preliminary results.  6th EUROPAD European Conference, Paris 1-3/XI/04, pp: 24-25 

Pizarro N., Fonseca F., Calpe X., Farré M.,  Martín-Santos R.,  Torrens M., de la Torre R. Enantioselective determination of methadone and its metabolites in plasma and salive from methadone maintenance patients  6th EUROPAD European Conference, París 1-3/XI/04 pp: 30.

Torrens M. Methadone plasma levels and of heroin. 6th EUROPAD European Conference, Paris 1-3/XI/04  pp: 19-20.

Dr  Eduard Vieta Pascual

Martinez-Aran A., Vieta E., Reinares M., Colom F., Torrent C., Sanchez-Moreno J., Benabarre A., Goikolea JM., Comes M., Salamero M. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004 Feb;161 (2):262-70.

Vieta E., Brugue E., Goikolea JM., Sanchez-Moreno J., Reinares M., Comes M., Colom F., Martinez-Aran A., Benabarre A., Torrent C. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol. 2004 Jan; 19(1 ):41-5.

Vieta E., Goikolea JM., Olivares JM., Gonzalez-Pinto A., Rodriguez A., Colom F., Comes M. Torrent C., Sanchez-Moreno J. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry. 2003 Jul;64(7):834-9.

Vieta E., Goikolea M., Benabarre A., Torrent C., Comes M., Martlnez-Aran A., Reinares M., Colom F., Parramon G., Corbella B., Gasto C. Treatment of bipolar I1 disorder with lamotrigine. Actas Esp Psiquiatr. 2003 Mar-Apr;31 (2):65-8. Spanish.

Vieta E., Torrent C., Sanchez-Moreno J., Martínez-Arán A., Goikolea JM., Benabarre A., Reinares M., Comes M., Corbella B., Colom F., Pichot P., Ezcurra J., González- Pinto A., Gutiérrez. Tratamiento psicofarmacológico de las depresiones. M (eds.). Intervención en crisis y tratamiento agudo de los trastornos psiquiátricos graves. Madrid, Aula Médica, 2003; 149-159

Corbella B, Vieta E. Molecular targets of lithium action. Acta Neuropsychiatrica, 2003; 15(6):316-340

Martínez-Arán A., Vieta E., Colom F., Reinares M., Benabarre A., Torrent C., Goikolea JM., Corbella B., Sánchez-Moreno J., Salamero M. Neuropsychological performance in depressed and euthymic bipolar patients. Neuropychobiology.2002;46 Suppl 1:16-21

Vieta E., Torrent C., Martínez-Arán A., Colom F., Reinares M., Benabarre A., Comes M., Goikolea JM. Una escala sencilla de evaluación del curso del trastorno bipolar: la CGI-BP-M. Actas Esp Psiquiatria. 2002; 30:301-304

Vieta E., Parramon G., Padrell E., Nieto E., Martinez-Aran A., Corbella B., Colom F., Reinares M., Goikolea JM., Torrent C. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2002 Oct; 4(5):335-40.

Martinez-Aran A., Vieta E., Torrent C., Sanchez-Moreno J., Goikolea J. M., Malhi G., Gonzalez-Pinto A., Daban C., Alvarez-Grandi S., Fountoulakis K., Krapinis G., Tabares-Seisdedos R., Ayuso-Mateos J. L. Functional outcome in bipolar disorder: the role of clinical and cognitive factors and medication. Bipolar Disorders (en premsa)

Martinez-Aran A., Vieta E., Colom F., Torrent C., Sanchez-Moreno J., Reinares M., Benabarre A., Goikolea JM., Brugue E., Daban C., Salamero M. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord. 2004;6:224-232

Martinez-Aran A., Vieta E., Colom F., Torrent C., Reinares M., Goikolea JM., Benabarre A., Comes M., Sanchez-Moreno J. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom. 2005;74:295-302

Colom F., Vieta E., Sanchez-Moreno J., Martinez-Aran A., Reinares M., Goikolea JM., Scott J. Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord. 2005;7 Suppl 5:32-36

Benabarre A., Vieta E. Martinez-Aran A., Garcia-Garcia M., Martin F., Lomena F., Torrent C., Sanchez-Moreno J., Colom F., Reinares M., Brugue E. , Valdes M. Neuropsychological disturbances and cerebral blood flow in bipolar disorder. Aust N Z J Psychiatry. 2005;39:227-234

Colom F., Lam D. Psychoeducation: improving outcomes in bipolar disorder. Eur Psychiatry. 2005;20:359-364

Torrent C., Martínez-Arán A., Daban C., Sánchez-Moreno J., Comes M.,  Goikolea JM., Salamero M., Vieta E. Cognitive impairment in bipolar II disorder. British Journal of Psychiatry (in press)